1 Introduction Dupilumab, a monoclonal antibody targeting the interleukin-4 receptor alpha, has transformed the management of moderate-to-severe atopic dermatitis. While it offers substantial relief for many patients, emerging reports have identified an adverse effect not highlighted in initial clinical trials: erythematous eruptions on the head and neck [1].